Speaker: Michael Kuss, Vice President, Analgesia, Premier Research
This webinar reviews the recent article in Pain by Cooper et al that summarizes the findings of a meeting convened by IMMPACT, the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials.
Importance of preclinical research
Key elements to consider in every acute pain analgesic study are:
Efficacy and safety in acute pain models. Fully characterizing these factors is essential to any analgesic trial. Efficacy attributes include onset of effect, maximum analgesic effect and duration of effect, and overall effect across the dosing interval. It’s also important to characterize the full adverse effect profile.
General research design considerations. A placebo treatment arm and a positive control arm are highly recommended.
Proof of concept and dose ranging. The initial proof-of-concept study should define the dose-response relationship, and comparator analgesics should be used as benchmarks for judging assay sensitivity and the relative efficacy of the investigational compound.
Choosing the right active comparator. In the absence of established standards, it’s wise to choose comparators whose mechanism of action is similar to the treatment under study.
The major efficacy domains in acute pain trials are pain intensity and pain relief. Additionally, analgesic onset and duration are important measures in most conditions. The webinar also will address documentation and reporting of adverse events and conclude with 10 best practices and principles that should be factored into every acute pain analgesia trial as recommended by the IMMPACT group.
Join us in exploring the current state of knowledge and experience for evaluating the efficacy and safety of medications that treat acute pain.